Voices
Jordi Remon: Crowded Space for Anti-TROP2 ADCs With Immunotherapy in First-Line NSCLC
Jordi Remon/X

Jordi Remon: Crowded Space for Anti-TROP2 ADCs With Immunotherapy in First-Line NSCLC

Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:

“Crowded Space for antiTROP2 ADC with IO in 1stL NSCLC.

OptitroptLung05 Trial, only China, report 65% risk of disease PD 65% with SaciTirua + pembro vs pembro in PDL1+ NSCLC. Geographical representation vs access to innovation as no approved by worldwide authorities?”

Jordi Remon: Crowded Space for Anti-TROP2 ADCs With Immunotherapy in First-Line NSCLC

AcceleRET-Lung: Pralsetinib Improves First-Line PFS In RET Fusion–Positive Advanced NSCLCJordi Remon: Crowded Space for Anti-TROP2 ADCs With Immunotherapy in First-Line NSCLC

cancer Jordi Remon Lung cancer NSCLC OncoDaily Oncology